DexCom's modelled fair value has been lifted modestly from US$91.64 to US$94.12 following second-quarter 2026 execution, new clinical data, and guidance updates. Several firms including Citi, Argus, Raymond James, Deutsche Bank, UBS, TD Cowen, Stifel and Mizuho raised price targets into a US$87 to US$105 range, citing strong margins, sensor rollout benefits, and potential payer coverage expansion including Medicare for Type 2 patients not on insulin. Truist and Mizuho noted a mixed setup for the broader medical technology sector, with investors still cautious on procedure volumes and capital spending. The updated model assumes revenue growth of about 11.20%, a net profit margin of about 21.85%, a future P/E multiple of about 26.4x, and a discount rate of about 7.55%.
DexCom IncFair value estimate lifted and multiple firms raised price targets after Q2 execution and clinical updates.
